文献速递消化系统肿瘤

奥拉帕利联合或不联合贝伐珠单抗对比贝伐珠单抗联合氟嘧啶作为晚期结直肠癌维持治疗的随机3期LYNK-003研究

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
PubMed 文献 · Eur J Cancer · 2024-03-21

LYNK-003是一项随机、开放标签、3期研究,评估不可切除或转移性结直肠癌诱导治疗后一线维持奥拉帕利联合或不联合贝伐珠单抗对比贝伐珠单抗联合氟嘧啶的疗效。预设中期无效性分析显示,奥拉帕利联合贝伐珠单抗组中位无进展生存期(PFS)为3.7个月,奥拉帕利单药组为3.5个月,贝伐珠单抗联合氟嘧啶组为5.6个月,研究因达到无效性标准而提前终止。

要点

  • 奥拉帕利联合贝伐珠单抗组中位PFS 3.7个月,对比贝伐珠单抗联合氟嘧啶组5.6个月,HR 1.52(95%CI 1.02-2.27)。
  • 奥拉帕利单药组中位PFS 3.5个月,对比贝伐珠单抗联合氟嘧啶组5.6个月,HR 2.11(95%CI 1.39-3.18)。
  • 治疗相关不良事件发生率分别为62%、50%和59%,无治疗相关死亡。

核心结论

  • LYNK-003研究因达到无效性标准而提前终止;维持奥拉帕利联合或不联合贝伐珠单抗对比贝伐珠单抗联合氟嘧啶未显示出临床疗效。

研究设计与样本

  • 随机、开放标签、3期LYNK-003研究。
  • 纳入年龄≥18岁、不可切除或转移性结直肠癌(mCRC)且在一线贝伐珠单抗联合5-氟尿嘧啶联合奥沙利铂联合亚叶酸钙(FOLFOX)或卡培他滨联合奥沙利铂(CAPOX)诱导后未进展的参与者。
  • 参与者按1:1:1随机分配至奥拉帕利联合贝伐珠单抗组、奥拉帕利单药组或贝伐珠单抗联合氟嘧啶(5-氟尿嘧啶或卡培他滨)组。
  • 主要终点为盲态独立中心审查根据RECIST v1.1评估的无进展生存期(PFS)。
  • 2020年8月至2022年5月期间,共309名参与者被分配至奥拉帕利联合贝伐珠单抗组(n=104)、奥拉帕利单药组(n=107)或贝伐珠单抗联合氟嘧啶组(n=98)。

主要发现

  • 中期分析时,中位随访时间为7.6个月(范围0.1-19.7个月)。
  • 奥拉帕利联合贝伐珠单抗组中位PFS为3.7个月(95%CI 2.8-5.3),对比贝伐珠单抗联合氟嘧啶组5.6个月(95%CI 3.8-5.9),HR 1.52(95%CI 1.02-2.27;P=0.982)。
  • 奥拉帕利单药组中位PFS为3.5个月(95%CI 2.0-3.7),对比贝伐珠单抗联合氟嘧啶组5.6个月(95%CI 3.8-5.9),HR 2.11(95%CI 1.39-3.18;P=0.999)。
  • 治疗相关不良事件分别发生在奥拉帕利联合贝伐珠单抗组64例(62%)、奥拉帕利单药组52例(50%)和贝伐珠单抗联合氟嘧啶组57例(59%)参与者中。
  • 无治疗相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因达到无效性标准而提前终止。
  • 报告的是预设中期无效性分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The randomized, open-label, phase III LYNK-003 study assessed the efficacy of first-line maintenance olaparib, alone or in combination with bevacizumab, versus bevacizumab plus a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer (mCRC). We present results of the prespecified interim futility analysis. METHODS: Eligible participants were ≥18 years of age with unresectable or mCRC that had not progressed after induction with first-line bevacizumab plus 5-fluorouracil plus oxaliplatin plus leucovorin (FOLFOX) or capecitabine plus oxaliplatin (CAPOX). Participants were randomly assigned 1:1:1 to olaparib plus bevacizumab, olaparib alone, or bevacizumab plus a fluoropyrimidine (5-fluorouracil or capecitabine). The primary end point was progression-free survival (PFS) per RECIST v1.1 by central review. RESULTS: Between August 2020 and May 2022, 309 participants were assigned to olaparib plus bevacizumab (n = 104), olaparib (n = 107), or bevacizumab plus fluoropyrimidine (n = 98). At interim analysis, with a median follow-up of 7.6 months (range 0.1-19.7 months), the median PFS was 3.7 months (95% CI 2.8-5.3) with olaparib plus bevacizumab (HR 1.52; 95% CI 1.02-2.27; P = 0.982) and 3.5 months (95% CI 2.0-3.7) with olaparib (HR 2.11; 95% CI 1.39-3.18; P = 0.999) versus 5.6 months (95% CI 3.8-5.9) with bevacizumab plus fluoropyrimidine. Treatment-related adverse events occurred in 64 (62%), 52 (50%), and 57 (59%) participants, respectively. There were no treatment-related deaths. CONCLUSION: The LYNK-003 study was stopped prematurely as criteria for futility were met. Maintenance olaparib with or without bevacizumab did not demonstrate clinical efficacy compared with bevacizumab plus a fluoropyrimidine. GOV REGISTRATION: NCT04456699.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Takashima A, García-Alfonso P, Manneh R, et al. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. Eur J Cancer. 2024. PMID: 38749110. doi:10.1016/j.ejca.2024.114036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。